Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;8(1):41-54.
doi: 10.1038/nrd2760.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

P Jeffrey Conn  1 , Arthur Christopoulos, Craig W Lindsley
Affiliations
Review

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

P Jeffrey Conn et al. Nat Rev Drug Discov. 2009 Jan.

Abstract

Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands. However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Modes of action of allosteric modulators
a | Allosteric ligands bind to a topographically distinct site on a receptor to modulate orthosteric ligand affinity (red) and/or efficacy (blue). Some allosteric ligands can directly perturb signalling in their own right (green). b | Simulations show the effects on the binding (left) or function (right) of an orthosteric agonist mediated by three different allosteric potentiators: the first (red) enhances orthosteric agonist affinity only; the second (blue) enhances orthosteric agonist efficacy only; the third (green) modestly enhances both affinity and efficacy, and also displays allosteric agonism. Note the potential for differences in observed outcome depending on assay format and that the baseline is 50% specific binding.
Figure 2
Figure 2. Allosteric modulators of gPcr-associated signalling pathways
a | Chemical structures of allosteric modulators known to differentially modulate signalling pathways that are associated with a given G-protein-coupled receptor in a common cellular background. b | Differential effects of the allosteric modulator, N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA), on dihydroxyphenylglycol (DHPG)-mediated calcium signalling (left), or extracellular signal regulated kinase (ERK) 1/2 phosphorylation (right) through the endogenous mGluR5 receptor in rat cortical astrocytes. Data from ref. . M, motor; pERK1/2, phosphorylated ERK1/2; tERK1/2, total ERK1/2.
Figure 3
Figure 3. structures of the two marketed gPcr allosteric modulators
Cinacalet (compound 3) is a positive allosteric modulator of the calcium sensing receptor and is used to treat hyperparathyroidism. Maraviroc (compound 4) is a negative allosteric modulator of chemokine receptor 5 that inhibits HIV entry into cells and is used to treat HIV infections.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. George SR, O’Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 2002;1:808–820. - PubMed
    1. Spiegel AM. Mutations in G proteins and G protein-coupled receptors in endocrine disease. J. Clin. Endocrinol. Metab. 1996;81:2434–2442. - PubMed
    1. Rana BK, Shiina T, Insel PA. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 2001;41:593–624. - PubMed
    1. Howard AD, et al. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 2001;22:132–140. - PubMed
    1. Mohler HF, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 2002;300:2–8. - PubMed

LinkOut - more resources